TrialNatrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis
Trial details
- Registry ID
- NCT05363891
- Phase
- Phase 2
XBIT
XBiotech, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
3Trials in this database
5Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Natrunix or Placebo in Combination With Methotrexate in Rheumatoid ArthritisNCT05363891 | XBIT | Phase 2 | Completed | 2024-10-31Actual |
| Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for EfficacyNCT06526377 | XBIT | Phase 2 | Not yet recruiting | 2028-09Estimated |
| Natrunix in Combination With Methotrexate for Rheumatoid Arthritis TreatmentNCT06590090 | XBIT | Phase 2 | Not yet recruiting | 2027-01-15Estimated |
Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for Efficacy
Trial details
- Registry ID
- NCT06526377
- Phase
- Phase 2
Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment
Trial details
- Registry ID
- NCT06590090
- Phase
- Phase 2
Latest recorded trial changes
Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for Efficacy
NCT06526377 · XBiotech, Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Assessment of Spondyloarthritis International Society (ASAS) criteria will be used to determine proportion of subjects achieving 40% Improvement (ASAS40 response)
+ After
Measure: Percentage of participants achieving ASAS40.
Planned enrollment increased by 90 participants
− Before
60 participants (planned)
+ After
150 participants (planned)
Primary completion date changed
− Before
28 Feb 2027
+ After
Sep 2028
Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for Efficacy
NCT06526377 · XBiotech, Inc.
Primary completion date changed
− Before
28 Feb 2025
+ After
28 Feb 2027
Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment
NCT06590090 · XBiotech, Inc.
Primary completion date changed
− Before
15 Jan 2026
+ After
15 Jan 2027